ライフサイエンスコーパス: letrozole

1 us letrozole; n = 25 received degarelix plus letrozole).

2 c administration of the aromatase inhibitor, letrozole.

3 s letrozole (2.5 mg per day) or placebo plus letrozole.

4 a embryo freezing with the concurrent use of letrozole.

5 after treatment with the aromatase inhibitor letrozole.

6 end points continued to show trends favoring letrozole.

7 1 mutations responded well to everolimus and letrozole.

8 h a clinical dose of the aromatase inhibitor letrozole.

9 gan but was not blocked by pretreatment with letrozole.

10 an in women, and brain uptake was blocked by letrozole.

11 s was increased, which could be inhibited by letrozole.

12 eroidal aromatase inhibitors anastrozole and letrozole.

13 pre-treatment with the aromatase inhibitor, letrozole.

14 ed a cell line model of resistance to the AI letrozole.

15 atively, the use of a more potent AI such as letrozole.

16 ns for memory deficits in women treated with letrozole.

17 sensitivity to the aromatase inhibitor (AI) letrozole.

18 ation of breast cancer cells to estrogen and letrozole.

19 poorest prognosis and may benefit most from letrozole.

20 re repeated 2 h after ingestion of 2.5 mg of letrozole.

21 pared to anastrozole and to palbociclib plus letrozole.

22 s were enrolled and 70 completed 6 months of letrozole.

23 666), in which 2,458 (5.3%) mothers received letrozole.

24 breast were determined at baseline and after letrozole.

25 exposure misclassification in the example of letrozole.

26 and non-tumor regions at baseline and after letrozole.

27 reversed by withdrawal and reintroduction of letrozole.

28 ree survival compared with continuous use of letrozole.

29 AI therapy with anastrozole, exemestane, or letrozole.

30 0.24-0.77), abemaciclib plus anastrozole or letrozole (0.42; 0.23-0.76), palbociclib plus fulvestran

31 e interval [CrI] 0.25-0.70), ribociclib plus letrozole (0.43; 0.24-0.77), abemaciclib plus anastrozol

32 eater with palbociclib plus letrozole versus letrozole (-0.80 v -0.42; P < .001).

33 ars with node-positive disease, 65% received letrozole (122 of 188).

34 se-free interval, to receive continuous oral letrozole 2.5 mg daily or continuous oral letrozole 2.5

35 al letrozole 2.5 mg daily or continuous oral letrozole 2.5 mg daily plus oral palbociclib 125 mg, giv

36 eoperative therapy consisting of 6 months of letrozole 2.5 mg orally daily plus lapatinib 1,500 mg or

37 Patients were treated with letrozole 2.5 mg per day for 6 months before surgery.

38 cancer were randomly assigned (2:1) to POAI (letrozole 2.5 mg per day orally or anastrozole 1 mg per

39 SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles.

40 andomly assigned (1:1) to receive 5 years of letrozole (2.5 mg orally per day) or placebo.

41 multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) with or without bevaci

42 y on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day) or placebo plus letrozole.

43 d tamoxifen for >/= 1 year were treated with letrozole (2.5 mg) daily for >/= 2 years.

44 gned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day fo

45 to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 w

46 treatment groups of either continuous use of letrozole (2.5 mg/day orally for 5 years) or intermitten

47 y orally for 5 years) or intermittent use of letrozole (2.5 mg/day orally for 9 months followed by a

48 ice or web-based response system, to receive letrozole (2.5 mg/day orally, continuously) with either

49 s of a 4-week daily administration of the AI letrozole (20 mug, p.o.) on cognition, anxiety, thermore

50 nadotropin (301 women), clomiphene (300), or letrozole (299).

51 e final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]).

52 ith palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P < .001) in the 190 evaluable p

53 de 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P < .001) mainly because of as

54 t activity, the multiple gestation rate with letrozole (9 of 67 pregnancies, 13%) did not differ sign

55 ss in female mice that had been treated with letrozole, a potent aromatase inhibitor.

56 More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%

57 sion of both estrogen types was greater with letrozole across the full range of BMIs in this study.

58 anada trial MA.17 demonstrated benefits with letrozole after 5 years of tamoxifen, oncologists needed

59 , 84 to palbociclib plus letrozole and 81 to letrozole alone.

60 ENT plus letrozole also prevented lung colonization and growth of

61 ase activity required only one-fifth as much letrozole (an AI) in the presence of 25 nM LBH589 as in

62 ments consisted of estradiol, an ER agonist; letrozole, an aromatase inhibitor; and fulvestrant, a pu

63 third generation aromatase inhibitors (AIs) letrozole, anastrozole, and the steroidal exemestane wer

64 classified as having a clinical response to letrozole and 15 being clinically resistant.

65 ssigned 165 patients, 84 to palbociclib plus letrozole and 81 to letrozole alone.

66 95% confidence interval [CI], 93 to 96) with letrozole and 91% (95% CI; 89 to 93) with placebo (hazar

67 all survival was 93% (95% CI, 92 to 95) with letrozole and 94% (95% CI, 92 to 95) with placebo (hazar

68 ence of contralateral breast cancer (67 with letrozole and 98 with placebo) and 200 deaths (100 in ea

69 aspects of low adherence (early cessation of letrozole and a compliance score of < 90%) were associat

70 Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups.

71 On the basis of clinical response rates, letrozole and anastrozole were selected for further inve

72 Combination letrozole and bevacizumab was feasible with expected bev

73 The letrozole and buparlisib combination was safe, with reve

74 servation after ovarian stimulation with the letrozole and follicle-stimulating hormone protocol pres

75 after treatment with the aromatase inhibitor letrozole and identified a D189Y mutation in the inhibit

76 ificantly different between palbociclib plus letrozole and letrozole groups ( P = .20; complete respo

77 ione to physiologically ineffective doses of letrozole and oxidative stress byproducts produces AIMSS

78 re enrolled and randomly assigned to receive letrozole and placebo (n=168) or letrozole and taselisib

79 No significant differences between letrozole and placebo were observed in scores on most su

80 ed the feasibility of a short-term course of letrozole and sought to determine whether treatment resu

81 and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively.

82 to receive letrozole and placebo (n=168) or letrozole and taselisib (n=166).

83 se events as a result of both degarelix plus letrozole and triptorelin plus letrozole were as expecte

84 ILC who responded to 3 months of neoadjuvant letrozole and were compared with a cohort of 14 respondi

85 The genes that change on letrozole are highly consistent between ILC and IDC.

86 Further longer-term studies with letrozole are needed in MAS.

87 cancer treated with the AIs anastrozole and letrozole are related to BMI.

88 sease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendme

89 efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advan

90 the effects of combination palbociclib plus letrozole as neoadjuvant therapy.

91 Letrozole, but not anastrozole, decreased bleeding episo

92 east cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroducti

93 y potency on aromatase comparable to that of letrozole chosen as a reference compound.

94 treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred in 35.5%, 28.3%

95 More women in the letrozole cohort had tumors larger than 2.0 cm (44.2% v

96 e in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P < .001

97 ole was significantly attenuated by DHA, and letrozole completely inhibited this suppressive action.

98 Novel ruthenium-letrozole complexes have been prepared, and cell viabili

99 d androstenedione levels cooperated with low letrozole concentrations and inflammatory mediators were

100 Conclusion Letrozole did not demonstrate significantly superior eff

101 breast cancer, extended use of intermittent letrozole did not improve disease-free survival compared

102 Adding temsirolimus to letrozole did not improve PFS as first-line therapy in p

103 equential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole

104 days (12.7/1,000 pregnancies) overestimated letrozole exposure during pregnancy by 8.4-fold and 2.3-

105 tly, breast cancer patients who responded to letrozole expressed significantly lower Cdc6 than those

106 Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluatio

107 with SE </=1.1%) for letrozole monotherapy, letrozole followed by tamoxifen, and tamoxifen followed

108 trozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks.

109 :2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole t

110 ears, 1548 to tamoxifen for 5 years, 1540 to letrozole for 2 years followed by tamoxifen for 3 years,

111 randomly assigned to letrozole for 5 years, letrozole for 2 years followed by tamoxifen for 3 years,

112 nd 1548 to tamoxifen for 2 years followed by letrozole for 3 years.

113 years, or tamoxifen for 2 years followed by letrozole for 3 years.

114 of the trial, 1546 were randomly assigned to letrozole for 5 years, 1548 to tamoxifen for 5 years, 15

115 d patients enrolled and randomly assigned to letrozole for 5 years, letrozole for 2 years followed by

116 d patients randomly assigned to tamoxifen or letrozole for 5 years.

117 fen for 5 years and 2463 to monotherapy with letrozole for 5 years.

118 to assess the effect of the extended use of letrozole for an additional 5 years.

119 ve CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal

120 reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21

121 In premenopausal women receiving letrozole for neoadjuvant endocrine therapy, OFS was ach

122 s significantly better than palbociclib plus letrozole for progression-free survival.

123 Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass

124 reduction in the hazard of a DFS event with letrozole for the LB subtype (HR, 0.65; 95% CI, 0.53 to

125 breast cancer and were receiving neoadjuvant letrozole for transcript profiling.

126 and that the combination of ovariectomy and letrozole further reduced the frequency of large lesions

127 red with 87.5% (86.0-88.8) in the continuous letrozole group (hazard ratio 1.08, 95% CI 0.93-1.26; p=

128 11.2-not estimable) for the palbociclib plus letrozole group (HR 0.299, 0.156-0.572; one-sided p<0.00

129 months (13.8-27.5) for the palbociclib plus letrozole group (HR 0.488, 95% CI 0.319-0.748; one-sided

130 months (13.1-27.5) for the palbociclib plus letrozole group (HR 0.508, 0.303-0.853; one-sided p=0.00

131 pregnancy loss (49 of 154 pregnancies in the letrozole group [31.8%] and 30 of 103 pregnancies in the

132 survival was 11.1 months (7.1-16.4) for the letrozole group and 18.1 months (13.1-27.5) for the palb

133 al was 10.2 months (95% CI 5.7-12.6) for the letrozole group and 20.2 months (13.8-27.5) for the palb

134 e survival was 5.7 months (2.6-10.5) for the letrozole group and 26.1 months (11.2-not estimable) for

135 [95% CI 27.9-36.0] for the palbociclib plus letrozole group and 27.9 months [25.5-31.1] for the letr

136 54 patients (24 [1%] in the intermittent letrozole group and 30 [1%] in the continuous letrozole

137 events had occurred in the palbociclib plus letrozole group and 59 in the letrozole group.

138 11 (13%) patients in the palbociclib plus letrozole group and two (2%) in the letrozole group disc

139 85.8% (95% CI 84.2-87.2) in the intermittent letrozole group compared with 87.5% (86.0-88.8) in the c

140 lib plus letrozole group and two (2%) in the letrozole group discontinued the study because of advers

141 (54%) of 83 patients in the palbociclib plus letrozole group versus one (1%) of 77 patients in the le

142 were four major congenital anomalies in the letrozole group versus one in the clomiphene group (P=0.

143 nsion (584 [24%] of 2417 in the intermittent letrozole group vs 517 [21%] of 2411 in the continuous l

144 3 [<1%] of 2417 patients in the intermittent letrozole group vs ten [<1%] of 2411 in the continuous l

145 e rate of contralateral breast cancer in the letrozole group was 0.21% (95% CI, 0.10 to 0.32), and th

146 ore than one patient in the palbociclib plus letrozole group were pulmonary embolism (three [4%] pati

147 he most common grade 4 adverse events in the letrozole group were urinary tract infection, hypokalaem

148 group vs 517 [21%] of 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]).

149 ebo group vs 50 [3%] of 1941 patients in the letrozole group) and back pain (44 [2%] vs 38 [2%]).

150 etrozole group and 30 [1%] in the continuous letrozole group) had grade 3-5 CNS cerebrovascular ischa

151 le group and 27.9 months [25.5-31.1] for the letrozole group), 41 progression-free survival events ha

152 group vs ten [<1%] of 2411 in the continuous letrozole group).

153 group versus one (1%) of 77 patients in the letrozole group, leucopenia in 16 (19%) versus none, and

154 lbociclib plus letrozole group and 59 in the letrozole group.

155 e placebo group and 84.7% (82.9-86.4) in the letrozole group.

156 se-free survival events were reported in the letrozole group; hazard ratio 0.85, 95% CI 0.73-0.999; p

157 erent between palbociclib plus letrozole and letrozole groups ( P = .20; complete response + partial

158 points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were change in Ki-67 (p

159 ll multiple gestations in the clomiphene and letrozole groups were twins, whereas gonadotropin treatm

160 Women who received letrozole had more cumulative live births than those who

161 patients assigned to receive triptorelin and letrozole had suboptimal OFS after cycle 1 (six events d

162 Ovarian stimulation with letrozole has been proposed to reduce multiple gestation

163 hazard of a disease-free survival event with letrozole (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.01

164 Palbociclib plus letrozole (HR 0.42; 95% credible interval [CrI] 0.25-0.7

165 The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC,

166 rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients.

167 observed, thermoregulation was disrupted by letrozole in females only, indicating some impact on hyp

168 as inhibited either by tamoxifen in vitro or letrozole in human subjects.

169 y test CDK4/6 inhibitors in combination with letrozole in independent two-arm trials.

170 ncer outcome compared with continuous use of letrozole in postmenopausal women.

171 rate the synergistic interaction of LBH589 + letrozole in suppressing the proliferation of hormone-re

172 s significantly better than palbociclib plus letrozole in terms of the proportion of patients achievi

173 The addition of palbociclib to letrozole in this phase 2 study significantly improved p

174 tment of BMS-754807 with either tamoxifen or letrozole in vivo elicited tumor regressions not achieve

175 institution phase II trial of everolimus and letrozole in women with recurrent EC.

176 of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might

177 ate were similarly attenuated by infusion of letrozole into the median eminence of the hypothalamus.

178 their cytotoxicity to cancer cells, whereas letrozole is an aromatase inhibitor administered after s

179 Letrozole is an aromatase inhibitor that has an unapprov

180 The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular

181 + complete response) were observed (70% for letrozole-lapatinib and 63% for letrozole-placebo).

182 en receptor-positive/HER2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a

183 In the letrozole-lapatinib arm, the probability of achieving a

184 The combination of letrozole-lapatinib in early breast cancer was feasible,

185 tion between PIK3CA mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early b

186 ur-arm option to 5 years of tamoxifen (Tam), letrozole (Let), or the agents in sequence (Let-Tam, Tam

187 arelix and letrozole than to triptorelin and letrozole (median, 3 v 14 days; hazard ratio, 3.05; 95%

188 yndrome, but aromatase inhibitors, including letrozole, might result in better pregnancy outcomes.

189 ndocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequent

190 5-year tamoxifen monotherapy arm or a 5-year letrozole monotherapy arm.

191 c breast cancer might be good candidates for letrozole monotherapy in the first-line setting regardle

192 Comparison of sequential treatments to letrozole monotherapy included patients enrolled and ran

193 8.7 years from randomisation (range 0-12.4), letrozole monotherapy was significantly better than tamo

194 ncer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen month

195 trozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies wh

196 o-treat estimates (each with SE </=1.1%) for letrozole monotherapy, letrozole followed by tamoxifen,

197 cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 ye

198 the comparison of the sequential groups with letrozole monotherapy, there were no statistically signi

199 (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and

200 nts were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075).

201 6 patients were randomly assigned to receive letrozole (n=1983) or placebo (n=1983).

202 e enrolled (n = 26 received triptorelin plus letrozole; n = 25 received degarelix plus letrozole).

203 (5a reductase inhibitor; AvodartTM); (d) T + Letrozole (nonsteroidal aromatase inhibitor; FemeraTM);

204 e used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm.

205 tocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen

206 tudy, we therefore focused on the effects of letrozole on long-term potentiation (LTP), which is an e

207 that synergized strongly in combination with letrozole or 4-hydroxytamoxifen and fulvestrant.

208 h endocrine therapy (an aromatase inhibitor [letrozole or anastrazole] or fulvestrant).

209 Previous therapy included letrozole or anastrozole (100%), tamoxifen (48%), fulves

210 signed 750 women, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles,

211 tor BMS-754807 alone and in combination with letrozole or tamoxifen.

212 s trastuzumab provided superior benefit over letrozole or trastuzumab alone.

213 ng 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June

214 There was no evidence that the benefit of letrozole over tamoxifen differed according to patients'

215 re repeated 2 hours after ingestion of 2.5mg letrozole p.o.

216 reduced the serotonin/prolactin response and Letrozole partially blocked the effect of T.

217 duced the risk of disease progression versus letrozole-placebo (hazard ratio [HR] = 0.71; 95% CI, 0.5

218 2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a similar overall clinical

219 ved (70% for letrozole-lapatinib and 63% for letrozole-placebo).

220 feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone rece

221 .6 months with letrozole to 20.2 months with letrozole plus bevacizumab.

222 onths with letrozole versus 47.2 months with letrozole plus bevacizumab.

223 valuate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant thera

224 creased Her-2 expression, the combination of letrozole plus trastuzumab provided superior benefit ove

225 Women with ER-positive tumors also received letrozole (plus a luteinizing hormone-releasing hormone

226 AIs, but although this was significant with letrozole (r = 0.35; P = .013, and r = 0.30; P = .035 fo

227 Letrozole reduced contralateral breast cancer frequency

228 ystemic administration of the AROM inhibitor letrozole reduced spine synapse density in the BL of adu

229 Pretreatment with letrozole reduced tracer uptake in most subjects, althou

230 Pretreatment with letrozole reduced tracer uptake in the majority of subje

231 A P450arom inhibitor, letrozole, reduced 17beta-estradiol levels and completel

232 ne dramatically lowered the concentration of letrozole required to engage TRPA1.

233 hat ENT treatment can be used to restore the letrozole responsiveness of ER-negative tumors.

234 lained infertility, ovarian stimulation with letrozole resulted in a significantly lower frequency of

235 al women with ER-positive DCIS, preoperative letrozole resulted in significant imaging and biomarker

236 Everolimus plus letrozole results in a high CBR and RR in patients with

237 his phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and preliminary activi

238 In addition, letrozole sex-specifically altered synaptic properties i

239 Adding palbociclib to letrozole significantly enhanced the suppression of mali

240 cultures from immature rats, treatment with letrozole significantly reduced spine synapses in the BL

241 patients (n = 219), addition of lapatinib to letrozole significantly reduced the risk of disease prog

242 xokinase-2 (HK2) in combination with the AI, letrozole, synergistically reduced cell viability in AI-

243 by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy

244 Those on letrozole/temsirolimus experienced more grade 3 to 4 eve

245 ratory analysis showed improved PFS favoring letrozole/temsirolimus in patients </= age 65 years (9.0

246 longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letroz

247 red more frequently among patients receiving letrozole than among those receiving placebo, including

248 tment with ENT alone and in combination with letrozole than in control tumors (P > 0.001).

249 aster for patients assigned to degarelix and letrozole than to triptorelin and letrozole (median, 3 v

250 he cumulative ovulation rate was higher with letrozole than with clomiphene (834 of 1352 treatment cy

251 les and were not sex-specifically altered by letrozole, the findings suggest sex-specific mechanisms

252 Two years of letrozole therapy did not increase predicted adult heigh

253 romatase inhibitor-based therapy, 5 years of letrozole therapy did not significantly prolong disease-

254 its is required before recommending extended letrozole therapy to patients with early-stage breast ca

255 ritish Columbia (BC), letters about extended letrozole therapy were sent to eligible BC women, their

256 While receiving adjuvant letrozole therapy, she reported 3 months of worsening ba

257 letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then

258 lbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole

259 ongation in median PFS from 15.6 months with letrozole to 20.2 months with letrozole plus bevacizumab

260 imity of this use to conception, we selected letrozole to study the effect of 3 different methods for

261 Letrozole-treated boys with idiopathic short stature (IS

262 In acute slices of letrozole-treated female mice with reduced estradiol ser

263 Letrozole treatment did not significantly improve diseas

264 tudy, we aimed to determine whether extended letrozole treatment improves disease-free survival after

265 Letrozole treatment was administered to both male and fe

266 During letrozole treatment, a decrease in BPE occurred in 46% (

267 pulation that compared extended intermittent letrozole use (n=2425) with continuous letrozole use (n=

268 ttent letrozole use (n=2425) with continuous letrozole use (n=2426).

269 median overall survival of 43.9 months with letrozole versus 47.2 months with letrozole plus bevaciz

270 The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio

271 stimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio

272 compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients

273 verse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3

274 polymerase was greater with palbociclib plus letrozole versus letrozole (-0.80 v -0.42; P < .001).

275 Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v

276 e-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received fo

277 Efficacy of letrozole versus tamoxifen for contralateral breast canc

278 For the monotherapy comparison of letrozole versus tamoxifen, we found a 9% relative reduc

279 venile (prepubertal) female rats, wash-in of letrozole virtually abolished long-term potentiation (LT

280 s was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily.

281 mary endpoints: the addition of taselisib to letrozole was associated with a higher proportion of pat

282 Treatment with 6-12 months of anastrozole or letrozole was associated with decreases in BPE, which oc

283 with a higher incidence of hot flushes, and letrozole was associated with higher incidences of fatig

284 As compared with clomiphene, letrozole was associated with higher live-birth and ovul

285 The molecular response to letrozole was characterized and a four-gene classifier o

286 ant trend toward prolonged PFS for lapatinib-letrozole was seen in patients who experienced relapse l

287 was 10.9 QALMs compared with strategy B when letrozole was used as systemic therapy, whereas it was o

288 owed by tamoxifen, and tamoxifen followed by letrozole were 78.6%, 77.8%, 77.3% for disease-free surv

289 egarelix plus letrozole and triptorelin plus letrozole were as expected.

290 he changes in gene expression in response to letrozole were highly similar between responding ILC and

291 nd 18.7%, respectively; pregnancy rates with letrozole were significantly lower than the rates with s

292 The sequence of effects in response to letrozole were similar in ovariectomized female and male

293 l patients assigned to receive degarelix and letrozole, whereas 15.4% of patients assigned to receive

294 ced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth

295 up) 1-98 randomized clinical trial comparing letrozole with tamoxifen as adjuvant therapy for postmen

296 zole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the

297 ved adjuvant radiation therapy and initiated letrozole, with excellent compliance during the interval

298 d that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared w

299 tested whether taselisib in combination with letrozole would result in an increased proportion of obj

300 a levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, octreotide, and human growth hormone